Sansure Biotech Inc. (SHA:688289)
China flag China · Delayed Price · Currency is CNY
14.76
-0.25 (-1.67%)
Nov 17, 2026, 3:00 PM CST

Sansure Biotech Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,6241,6161,424991.16,3044,342
Other Revenue
25.5725.5734.1416.02146.58172.86
1,6501,6421,4581,0076,4504,515
Revenue Growth
-1.19%12.58%44.78%-84.39%42.88%-5.22%
Cost of Revenue
479.32420.23279.71280.962,9121,283
Gross Profit
1,1701,2211,178726.153,5383,232
Selling, General & Admin
854.24823.38749.79547.37939.48488.21
Research & Development
231.48226.44276.64194.81331.2186.84
Other Operating Expenses
10.685.8510.960.127.3112.48
Operating Expenses
1,1241,0871,051747.231,344706.01
Operating Income
46.56133.85127.26-21.082,1942,526
Interest Expense
-26.9-23.29-18.4-2.41-2.09-0.83
Interest & Investment Income
74.6486.8297.53308.4148.3532.53
Currency Exchange Gain (Loss)
1.721.726.854.315.04-42.25
Other Non Operating Income (Expenses)
-18.57-1.36-17.1-9.15-7.94-1.61
EBT Excluding Unusual Items
77.46197.74196.14280.082,2372,513
Impairment of Goodwill
-1.94-1.94---1.44-
Gain (Loss) on Sale of Investments
40.33-6.66-20.4461.8479.2481.01
Gain (Loss) on Sale of Assets
-12.25-5.36-4.21-7.21-5.470.41
Asset Writedown
-17.79-6.49-1.25--15.1-
Other Unusual Items
-2.2-2.290.3675.7621.321.37
Pretax Income
83.59175.08260.61410.482,3162,616
Income Tax Expense
13.9921.1634.3462.31379.21373.68
Earnings From Continuing Operations
69.6153.92226.27348.171,9372,243
Minority Interest in Earnings
42.0645.0149.3215.550.090.17
Net Income
111.66198.94275.6363.721,9372,243
Net Income to Common
111.66198.94275.6363.721,9372,243
Net Income Growth
-58.87%-27.82%-24.23%-81.22%-13.64%-14.29%
Shares Outstanding (Basic)
584585586587585589
Shares Outstanding (Diluted)
584585586587585589
Shares Change
-13.34%-0.22%-0.05%0.26%-0.59%6.55%
EPS (Basic)
0.190.340.470.623.313.81
EPS (Diluted)
0.190.340.470.623.313.81
EPS Growth
-52.54%-27.66%-24.19%-81.27%-13.12%-19.56%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-111.39-185.81-146.66-347.812,0001,504
Free Cash Flow Per Share
-0.19-0.32-0.25-0.593.422.56
Dividend Per Share
0.5260.5230.5250.4621.2980.760
Dividend Growth
-2.05%-0.38%13.59%-64.39%70.77%0%
Gross Margin
70.95%74.40%80.82%72.10%54.85%71.58%
Operating Margin
2.82%8.15%8.73%-2.09%34.01%55.94%
Profit Margin
6.77%12.12%18.90%36.12%30.03%49.68%
Free Cash Flow Margin
-6.75%-11.32%-10.06%-34.53%31.01%33.32%
EBITDA
292.54335.46269.7179.82,2692,571
EBITDA Margin
17.73%20.44%18.50%7.92%35.18%56.96%
D&A For EBITDA
245.98201.61142.45100.8875.4745.89
EBIT
46.56133.85127.26-21.082,1942,526
EBIT Margin
2.82%8.15%8.73%-2.09%34.01%55.94%
Effective Tax Rate
16.74%12.08%13.18%15.18%16.37%14.28%
Revenue as Reported
1,6501,6421,4581,0076,4504,515
Advertising Expenses
-58.7468.0726.2836.3632.38